Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma MPM: Phase II biomarker data from the LUME Meso study

A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer

Osimertinib vs standard of care SoC EGFR-TKI as first-line therapy in patients pts with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes

Health-related quality of life QoL after prophylactic cranial irradiation PCI vs no PCI for stage III NSCLC patients: Results from the NVALT-11/DLCRG-02 study

Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes

EGFR clonality and tumor mutation burden TMB analysis based on circulating tumor DNA ctDNA sequencing in advanced non-small cell lung cancer NSCLC

Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/ bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC IMpower150

Patient-reported outcomes from FLAURA: Osimertinib versus standard of care SoC epidermal growth factor receptor tyrosine kinase inhibitor EGFR-TKI in patients with EGFR-mutated advanced non-small cell lung cancer NSCLC

TTFields concurrent with standard of care for stage 4 non-small cell lung cancer NSCLC following platinum failure: Phase 3 LUNAR study

Treatment switchingadjusted overall survival OS in KEYNOTE-024: First-line pembrolizumab versus chemotherapy in patients with advanced non-small cell lung cancer NSCLC

PALB2 mRNA expression as a predictive marker in advanced non-small cell lung cancer NSCLC patients p treated with docetaxel-cisplatin

A multi-center, prospective, randomized controlled clinical trial: Comparison between wedge resection and segmentectomy in the surgical treatment of ground glass opacity-dominant stage IA non-small cell lung cancer

Circulating microRNAs as novel predictive markers of afatinib efficacy in squamous cell lung cancer SCC: An exploratory sub-analysis of the LUX-Lung 8 trial

Preliminary assessment of a targeted break-point NGS assay for ALK gene fusion detection in lung adenocarcinoma samples from Chilean patients

Circulating miR-31 as a predictive marker of EGFR TKI treatment efficacy in squamous cell lung cancer SCC: A sub-analysis of the LUX-Lung 8 trial